S. Byrne et al., CLINICAL-EVALUATION OF MEROPENEM VERSUS CEFTAZIDIME FOR THE TREATMENTOF PSEUDOMONAS SPP INFECTIONS IN CYSTIC-FIBROSIS PATIENTS, Journal of antimicrobial chemotherapy, 36, 1995, pp. 135-143
Cystic fibrosis patients (children and young adults) with Pseudomonas
spp. chest infections were treated with meropenem or ceftazidime. This
study was the first to investigate the use of meropenem in cystic fib
rosis. Meropenem was well tolerated with only transient elevations of
serum transaminases. No patient experienced nausea and vomiting, even
when meropenem was administered as a bolus injection. This allowed hom
e therapy to be used. Meropenem appeared to be at least as active as c
eftazidime even at the low doses used. Patients showed a greater impro
vement in respiratory function on meropenem than ceftazidime. Only one
patient (out of 60 courses) failed to respond to meropenem (98% succe
ss rate) compared with two failures out of 21 episodes with ceftazidim
e (90% success rate). There was little emergence of resistance to mero
penem even though some patients were treated up to eight times over a
2 year period.